RBC Capital Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained a 'Sector Perform' rating on Beam Therapeutics (NASDAQ:BEAM) and increased the price target from $27 to $35.
February 28, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained a 'Sector Perform' rating on Beam Therapeutics and raised the price target from $27 to $35.
The increase in price target by RBC Capital suggests a positive outlook on Beam Therapeutics' stock, potentially leading to increased investor confidence and a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100